Related Experiment Videos
[Effects of domperidone suppository against adverse reactions in digestive organs induced by cancer chemotherapy]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1984
Abstract:
We examined the effects of domperidone suppository against adverse reactions in digestive organs to antitumor agents. Suppositories containing 60 mg of domperidone were given to 15 patients who were suffering from vomiting and nausea occurring with the use of antitumor agents, and the changes in each digestive symptom were evaluated overall. As a result, 13 patients out of 15 (86.7%) showed improvement of symptoms. There were no adverse reactions to domperidone suppositories.
Insights
Domperidone suppositories effectively reduced nausea and vomiting in 86.7% of patients undergoing antitumor therapy. This study found no adverse reactions to the domperidone treatment.
Area of Science:
- Gastroenterology
- Pharmacology
Context:
- Antitumor agents frequently cause adverse reactions in the digestive system, including nausea and vomiting.
- Managing these side effects is crucial for patient tolerance and adherence to cancer treatment.
Purpose:
- To evaluate the efficacy and safety of domperidone suppositories in mitigating gastrointestinal adverse reactions associated with antitumor therapy.
- To assess the impact of domperidone on symptoms like nausea and vomiting in cancer patients.
Summary:
- Domperidone suppositories (60 mg) were administered to 15 patients experiencing nausea and vomiting due to antitumor agents.
- Overall symptom improvement was observed in 13 out of 15 patients (86.7%).
- No adverse reactions were reported for the domperidone suppositories.
Impact:
- Domperidone suppositories present a safe and effective option for managing chemotherapy-induced nausea and vomiting.
- Improved symptom control can enhance patient quality of life during antitumor treatment.